To explore the clinical features and prognosis of CD20-positive extranodal NK/T cell lymphoma. To analyze the clinical characteristics and prognosis of 11 ENKTL patients admitted to this hospital. Among the 11 patients, 6 cases with elevated LDH, 6 cases of anemia, and 8 cases with Ki-67≥50%. Two cases survived; 1 case lost contact; 8 cases died, and the average survival time of 8 cases was 22.5 months. The diagnosis of CD20 positive ENKTL is difficult, which requires a combination pathomorphology, immunohistochemistry, EBER and gene rearrangement detection and improve the understanding of the disease.Early diagnosis and active treatment is important.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10128480 | PMC |
| http://dx.doi.org/10.13201/j.issn.2096-7993.2021.05.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary gingival diffuse large B‑cell lymphoma with muscle invasion: A case report.
Oncol Lett
April 2025
Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Primary gingival diffuse large B-cell lymphoma (DLBCL) with muscle invasion is rare and accounts for ~0.5% of all reported cases of extranodal lymphoma. The present study describes the case of a 49-year-old man that initially presented at Yingshan County People's Hospital (Nanchong, China) in August 2017 with a chief complaint of tenderness and swelling of the jaw.
View Article and Find Full Text PDFAssessment of the Use of Available Resources for Diagnosing Diffuse Large B-Cell Lymphoma in an HIV-Prevalent Setting.
Int J Lab Hematol
March 2025
Department of Molecular Medicine and Haematology, University of Witwatersrand Medical School and National Health Laboratory Service, Johannesburg, Gauteng, South Africa.
Background: Limited availability of diagnostic tests in low-resource settings hampers the diagnosis and classification of diffuse large B-cell lymphoma (DLBCL). A study was performed to assess the use of resources for classifying DLBCL in South Africa (SA) using 'essential' and 'desirable' investigations as per published guidelines.
Methods: A record review was performed of 74 patients newly diagnosed with DLBCL by tissue biopsy at the National Health Laboratory Service (NHLS) in Johannesburg between 1 January 2019 and 31 December 2022.
Background: The treatment landscape for relapsed or refractory (R/R) follicular lymphoma (FL) has changed with the introduction of anti-CD19 chimeric antigen receptor T-cell therapies, including lisocabtagene maraleucel (liso-cel) and CD20 × CD3 bispecific T-cell-engaging monoclonal antibodies such as mosunetuzumab. Liso-cel and mosunetuzumab have demonstrated positive benefit-risk profiles for third-line or later (3L+) treatment of patients with R/R FL and are approved treatments for these patients. In the absence of a prospective, randomized study, we conducted an unanchored matching-adjusted indirect comparison (MAIC) to assess the efficacy and safety of liso-cel and mosunetuzumab for 3L+ treatment in patients with R/R FL.
View Article and Find Full Text PDFObjective: To investigate the risk factors for severe acute COVID-19 outcomes in the Omicron era among individuals with systemic autoimmune rheumatic diseases (SARDs).
Methods: We identified patients with confirmed SARDs and COVID-19 (positive PCR and/or antigen test) from 1 September 2022 to 15 March 2024 in the Mass General Brigham healthcare system. We estimated the associations of baseline characteristics with the odds of hospitalisation due to COVID-19 infection, verified by medical record review, using multivariable logistic regression.
Similarities and differences of a proliferation-inducing ligand expression in lacrimal gland lesions of patients with IgG4-associated ophthalmic diseases and mucosa-associated lymphoid tissue lymphoma.
Front Immunol
March 2025
Department of Ophthalmology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Objective: This study aimed to investigate the expression condition of a proliferation-inducing ligand (APRIL) in lacrimal gland lesions of patients with IgG4-associated ophthalmic diseases (IgG4-ROD) and mucosa-associated lymphoid tissue (MALT) lymphoma.
Patients And Methods: Fifteen patients with IgG4-ROD, 3 with MALT lymphoma, and 1 with elevated IgG4 with lacrimal gland lesions, treated in West China Hospital of Sichuan University from April 2022 to November 2023, were included. Immunofluorescence staining was used to detect the expression of APRIL in the specimen of lacrimal gland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!